360Dx

NEW YORK – Investment bank Canaccord Genuity On Wednesday initiated coverage of CareDx and BillionToOne with Buy ratings and price targets of $65 per share and $120 per share, respectively.

NEW YORK — PixCell Medical said on Wednesday that it has struck a Canadian distribution agreement for its point-of-care HemoScreen CBC analyzer following the instrument's approval in that country. HemoScreen CBC uses disposable reagent cartridges, artificial intelligence-based analysis, and viscoelastic focusing technology to enable five-part differential complete blood count analysis.

NEW YORK – Liquid biopsy firm Senticell said on Tuesday that it has closed an oversubscribed seed financing round approaching $7 million to advance its red blood cell technology platform. The round's participants included The Venture City, Capital Factory, Scalpel Ventures, Evoce Capital, and a group of high-net-worth individuals. The firm's technology, which it licenses exclusively from the University of Pennsylvania, is built on red blood cell (RBC)-bound nucleic acids.

NEW YORK – Guardant Health announced on Tuesday that national medical benefit manager Carelon Healthcare Services will cover the firm's Shield blood test for colorectal cancer screening, effective Nov. 15. Carelon is one of the largest specialty benefits managers in the US and a subsidiary of one of the largest health insurance companies in the US, Elevance Health.

NEW YORK – Share prices of the omics, diagnostics, and clinical laboratory companies tracked by the GenomeWeb Top 40 rose 10 percent on average month over month in August, as the life science tools and diagnostics segments well outpaced the broader market. The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.

NEW YORK – Heidelberg Epignostix said on Tuesday that it has inked a strategic partnership with the UK National Health Service's Genomic Medicine Service (GMS) to bring the company's epigenetic classifiers into NHS genomic laboratory services. Financial terms of the deal were not disclosed. Under the partnership, Heidelberg Epignostix will deliver epigenetic tumor stratification to all GMS genomic laboratories, integrating them with established and forthcoming laboratory workflows.

NEW YORK — Fujirebio said on Tuesday that two of its blood-based neurological health diagnostics have been approved for the Canadian market. According to the Tokyo-based company, Health Canada has issued a Class II Medical Device license for its Lumipulse G NfL blood test, which is designed for the quantitative measurement of the neuroaxonal injury biomarker neurofilament light chain. NfL has also shown promise as a biomarker for multiple sclerosis.

NEW YORK – VedaBio announced on Tuesday that it has selected urgent care management company UCP Merchant Medicine as a partner to help position its CRISPR-based molecular diagnostics system prior to launch. The multi-year partnership aims to estimate demand, set price, and introduce VedaBio's 10-minute, amplification-free system to the urgent care channel via UCPMM's network of 78 health system clients and more than 300 urgent care centers prior to US Food and Drug Administration clearance.

NEW YORK – The Advanced Research Projects Agency for Health (ARPA-H) on Monday announced the awardees of its Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program. The agency, a part of the US Dept.

NEW YORK – A European team has been awarded a €2.5 million ($2.9 million) European Innovation Council grant to support the development of a new diagnostics platform targeting sepsis. The effort, called SepTech, will begin on Sept. 1 and run through August 2029. It involves a quartet of commercial and academic partners.